International Dermatology Outcome Measures (IDEOM): Report from the 2021 Annual Meeting
August 2022 | Volume 21 | Issue 8 | 867 | Copyright © August 2022
Published online July 29, 2022
Caterina Zagona-Prizio BSa, Jenna Yousif BSb, Carly Grant BSc, Manan Mehta BSa, David Rosmarin MD FAADd, Nanette Silverberg MDb, Jerry K.L. Tan MD FRCPCe, Cecilia Larocca MDf, Michi M. Shinohara MDg, Arash Mostaghimi MD MPA MPHc, Brian Kim MD MPRb, Susanne Gulliver BA MPHh, Wayne Gulliver MD FRCPCh,i, Daniel M. Siegel MD MSj, Lourdes Perez-Chada MD MMSc,k, Joseph F. Merola MD MMSc,k, Alice B. Gottlieb MD PhDb, April W. Armstrong MD MPHa
aDepartment of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, CA
bDepartment of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY
cDepartment of Dermatology, Brigham and Women’s Hospital, Harvard Medical School, Boston MA
dDepartment of Dermatology, Tufts Medical Center, Boston, MA
eFaculty of Medicine, Western University, London, ON, Canada
fDepartment of Dermatology, Harvard Medical School, Brigham and Women’s Hospital & Dana-Farber Cancer Institute, Boston, MA
gDivision of Dermatology, University of Washington, Seattle Cancer Care Alliance, Seattle, WA
hNewLab Clinical Research Inc., St. John's, Canada
iFaculty of Medicine, Memorial University of Newfoundland, St. John’s, Canada
jDepartment of Dermatology, SUNY Downstate Medical Center, Brooklyn, NY
kDepartment of Dermatology and Medicine, Division of Rheumatology, Harvard Medical School, Brigham and Women’s Hospital, Boston, MA
Abstract
Background: International Dermatology Outcome Measures (IDEOM) is a non-profit organization founded in 2013. It is composed of researchers and stakeholders who work to develop evidenced-based outcome measures to enhance research and treatment recommendations of dermatologic diseases.
Summary: The 2021 IDEOM Virtual Annual Meeting occurred from November 19-20, 2021. Contributions were made by leaders and stakeholders from the psoriasis, psoriatic arthritis, pediatric hidradenitis suppurativa, acne, vitiligo, actinic keratosis, alopecia areata, itch, and cutaneous lymphoma workgroups. The psoriasis, psoriatic arthritis, and actinic keratosis workgroups provided an overview of their respective instruments for treatment satisfaction and symptom measurement. The inaugural meetings of the itch, alopecia areata, and cutaneous lymphoma workgroups identified unmet needs of their respective diseases and future goals. The acne, vitiligo, and pediatric hidradenitis suppurativa workgroups discussed concerns of quality of life, instruments for symptom measurement, and screening tools. Additionally, a representative from the US Food and Drug Administration was in attendance and presented an update on topical drugs and generics. This report provides a summary of workgroup updates from the past year and future directions established during the meeting.
Key messages: This report summarizes progress made by each IDEOM workgroup at the 2021 IDEOM Virtual Annual Meeting.
J Drugs Dermatol. 2022;21(8):867-874. doi:10.36849/JDD.6974
INTRODUCTION
International Dermatology Outcome Measures (IDEOM) was founded in 2013 to address a need for evidence-based and consensus-driven outcome measures in dermatology.1 Clear outcome measures are critical in dermatology where there are often misconceptions surrounding patient progress and appropriate treatments. As a result, researchers, healthcare providers, and payers require objective, high-quality instruments to measure patient outcomes. Therefore, IDEOM sought to establish a framework modeled after Outcome Measures in Rheumatology (OMERACT) and utilizing Consensus-based Standards for the selection of health Measurement Instruments (COSMIN) guidelines. Central to IDEOM’s process is the involvement of patient, physician, industry, insurer, and government stakeholders in identifying needs and developing instruments.
IDEOM’s annual meeting is an opportunity for these key stakeholders to attend seminars, discuss workgroup progress and determine future directions. At the meeting, Dr. Markham Luke, the Director of Therapeutic Performance at the US Food
